10-K: ResMed Reports Strong FY26 Growth and Strategic Acquisitions

ResMed Inc. announced robust financial results for fiscal year 2026, with a 10% increase in net revenue and a 13% rise in gross profit, alongside strategic acquisitions to bolster its healthcare offerings.

Summary

• ResMed Inc. reported a 10% increase in net revenue for fiscal year 2026, reaching $5.65 billion, up from $5.15 billion in fiscal year 2025.
• Gross profit saw a 13% increase, totaling $3.45 billion, with gross margin improving to 61.1% from 59.4%.
• Net income rose to $1.52 billion, or $10.43 per diluted share, compared to $1.40 billion, or $9.51 per diluted share, in the prior year.
• The company acquired Noctrix Health, LLC, a medical device company focused on restless legs syndrome, expanding its clinical sleep health portfolio.
• ResMed entered into a definitive agreement to sell its MatrixCare business for $490 million, as part of a portfolio optimization strategy.
• Operating cash flow for fiscal year 2026 was $1.8 billion, and cash and cash equivalents stood at $1.5 billion as of June 30, 2026.
• Research and development expenses increased by 14% to $378 million, representing 6.7% of net revenue.
• Selling, general, and administrative expenses increased by 13% to $1.12 billion, reflecting investments in acquisitions and marketing.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively, reflecting strong revenue growth, increased profitability, and strategic acquisitions that expand the company's market reach.

Positives

• Net revenue increased by 10% to $5.65 billion in FY2026.
• Gross profit increased by 13% to $3.45 billion, with gross margin improving to 61.1%.
• Net income grew to $1.52 billion, or $10.43 per diluted share.
• Operating cash flow was strong at $1.8 billion.
• Acquisition of Noctrix Health, LLC expands the company's product portfolio into restless legs syndrome treatment.
• Increased investment in R&D by 14% to $378 million.
• Successful management of foreign currency impacts, with constant currency revenue growth of 8% overall.
• The company maintained compliance with debt covenants and had significant liquidity with $1.5 billion in cash and cash equivalents.

Negatives

• Selling, general, and administrative expenses increased by 13% to $1.12 billion, partly due to acquisition and marketing investments.
• Restructuring charges of $22 million were incurred for workforce planning activities.
• The company faces ongoing risks related to supply chain disruptions, global macroeconomic conditions, and potential regulatory changes.
• The effective income tax rate increased to 20.6% from 16.5% in the prior year, partly due to the implementation of the Pillar Two global minimum tax.

Risks

• Inability to compete with new and existing technology, including pharmaceutical advancements like GLP-1s for obesity and OSA.
• Consolidation in the healthcare industry and healthcare payment reform could adversely affect revenues and results of operations.
• Global macroeconomic conditions, including inflation, supply chain disruptions, tariffs, and currency fluctuations, could negatively impact operations and profitability.
• Cybersecurity threats and potential breaches could lead to material loss of business, legal liability, or reputational harm.
• Failure to successfully integrate acquired businesses or execute strategic initiatives, including divestitures.
• Dependence on third-party suppliers for components, with potential disruptions impacting manufacturing and sales.
• Regulatory risks, including potential delays or cancellations of product sales, introductions, or modifications due to FDA or similar foreign regulations.
• Failure to comply with extensive healthcare, data privacy, and AI regulations could result in significant liability and reputational harm.

Future Outlook

The company anticipates continued growth driven by its core sleep and breathing health markets, expansion into adjacent areas through acquisitions, and ongoing investment in digital health ecosystems. The sale of the MatrixCare business is expected to sharpen focus on core growth areas.

Management Comments

• We design innovative technology to empower people to live happier, healthier lives.
• Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective.
• By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.
• The acquisition expands our clinical sleep health portfolio into an adjacent area of unmet need.
• The transaction is the result of portfolio optimization to sharpen our focus on our core growth areas of sleep, breathing and connected home-based healthcare.

Industry Context

StockSavvy.ai notes that ResMed's performance aligns with broader trends in the digital health and connected care markets, emphasizing the growing importance of home-based healthcare solutions. The acquisition of Noctrix Health positions ResMed to capitalize on the expanding market for neurological disorder treatments.

Comparison to Industry Standards

• ResMed's revenue growth of 10% in FY2026 outpaces the general medical device industry average, which has seen more moderate growth in recent periods.
• The company's gross margin of 61.1% is strong and generally above the industry average for medical device manufacturers, reflecting efficient operations and pricing power.
• Investment in R&D as a percentage of revenue (6.7%) is consistent with or slightly higher than leading companies in the connected health and medical technology sectors, indicating a commitment to innovation.
• The company's strategic focus on digital health and cloud-connected devices aligns with industry shifts towards value-based care and remote patient monitoring, differentiating it from traditional device manufacturers.

Legal Proceedings

• ResMed is involved in ongoing patent infringement litigation with Cleveland Medical Devices Inc. concerning various ResMed connected devices and data platforms.
• ResMed has filed petitions for Inter Partes Review (IPR) of several Cleveland Medical patents, with some PTAB decisions already issued.
• A new patent infringement suit was filed by Cleveland Medical against ResMed Inc. in Delaware, focusing on VirtuOx's products and software.
• Fractus, S.A. filed a patent infringement suit against ResMed Corp. and ResMed Inc. related to antenna technology in ResMed's devices.
• A whistleblower complaint was filed alleging a conspiracy to overcharge the U.S. for CPAP products sold to the Veterans Administration; the plaintiff voluntarily dismissed the complaint against ResMed.

Stakeholder Impact

• Shareholders benefit from increased revenue, profitability, and strategic growth initiatives.
• Employees may see continued investment in R&D and potential integration of new teams from acquisitions.
• Customers (healthcare providers, HME providers) will continue to have access to ResMed's innovative sleep and breathing health solutions, with potential for expanded offerings through Noctrix.
• Patients will benefit from improved quality of life through advanced sleep and breathing therapies, with potential for new treatments for restless legs syndrome.

Next Steps

• Complete the sale of the MatrixCare business in the first quarter of fiscal year 2027.
• Continue to invest in research and development for new products and solutions.
• Integrate Noctrix Health, LLC into the company's operations.
• Focus on expanding digital health ecosystems and connected care solutions.
• Monitor and adapt to evolving global macroeconomic conditions and regulatory landscapes.

Key Dates

Recommendation

ResMed demonstrates strong financial performance and strategic execution, but the increasing R&D and SG&A expenses, coupled with ongoing litigation and the evolving regulatory landscape, warrant a cautious 'hold' rating. Investors should monitor the integration of Noctrix and the impact of the MatrixCare divestiture.

Keywords

ResMed, Sleep Apnea, CPAP, Breathing Health, Digital Health, Medical Devices, Residential Care Software, Acquisition